# FDA 483 - Creative Foam Corporation - February 04, 2026

Source: https://www.keypedia.com/records/483/creative-foam-corporation/668b5e6e-9469-458f-9ed8-bb4720ffd02d

> FDA 483 for Creative Foam Corporation on February 04, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Creative Foam Corporation
- Inspection Date: 2026-02-04
- Product Type: drugs
- Office Name: Division of Pharmaceutical Quality Operations III
- Summary: Creative Foam Corporation dba Mt. olive in Mooresville, IN, a repacker of drug products, was cited for a significant quality system deficiency. The firm failed to perform Annual Product Reviews for its drug products, including medicated (b)(4), since 2022, and lacked a procedure for conducting these reviews. This indicates a failure to adequately evaluate product quality standards and ensure ongoing compliance.

## Related Officers

- [Shannon L. Maisano](https://www.keypedia.com/people/shannon-l-maisano/2cce259d-0fbe-44ef-b43e-7292da739470)

Company: https://www.keypedia.com/companies/creative-foam-corporation/36c31765-a5cb-4e34-9013-3f54dcba5ed0

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iii/45bc2d0d-d731-4955-aeb5-59aa0b76e4f0